-
This Cholesterol Drug May Extend The Life Of Prostate Cancer Patients, Shows Study
17 Oct 2025 07:20 GMT
Last Updated:October 15, 2025, 14:59 IST
Analysis of more than 2,100 men in the SPARTAN and TITAN trials found that those taking this drug with apalutamide and hormone therapy had higher 3-year survival rates
Rapid Read
Summarized by AI.
+
+ Follow usOn …
-
More Than 140,000 Bottles of a Cholesterol Medication Have Been Recalled Nationwide
16 Oct 2025 04:07 GMT
Right now, 45% of U.S. adults between the ages of 60 and 79 take statins, a lipid-lowering prescription drug indicated to treat high levels of LDL or “bad” cholesterol. In fact, national data shows statins are the most commonly-prescribed medication among …
-
Amgen to sell cholesterol drug at 60% discount direct to US consumers
06 Oct 2025 14:01 GMT
… U.S. sales of its cholesterol medication Repatha at a discounted cash …
-
Amgen To Sell Cholesterol Drug For Approximately 60% Discount
06 Oct 2025 21:03 GMT
Amgen (AMGN) announced on Monday that eligible patients can access its drug Repatha at about a 60% discount from the current list price via its direct-to-patient program in the U.S.
The program, called AmgenNow, follows the Trump Administration’s push to …
-
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices
06 Oct 2025 18:48 GMT
Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab).
AMGN stock is trending lower. View the charts here.
This follows results demonstrating Repatha significantly reduced the risk of major …
-
Amgen to sell cholesterol drug at 60% discount to cash-paying US patients
06 Oct 2025 17:10 GMT
By Deena Beasley LOS ANGELES (Reuters) — Amgen (AMGN) on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest pharmaceutical company to respond to U.S. political …
-
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs
03 Oct 2025 17:52 GMT
Vertigo3d/E+ via Getty Images Esperion Therapeutics (NASDAQ:ESPR) announced it has reached a settlement with Dr. Reddy’s Laboratories (NYSE:RDY) regarding the latter’s bid to launch generic versions of NEXLETOL and NEXLIZET in the U.S. Under the …
-
Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs
03 Oct 2025 13:40 GMT
Esperion Therapeutics (ESPR) on Friday said that it has entered into a settlement agreement with Dr. Reddy’s Laboratories under which the latter has agreed not to market a generic version of either Nexletol or Nexlizet in the United States before April 19, …
-
7 million taking cholesterol drug urged 'don't eat this fruit' because of side effects
29 Sep 2025 07:17 GMT
… damage."
Regarding the anti-cholesterol medication, she continued: "Statins, often …
-
Regeneron nabs FDA label expansion for Ultragenyx-partnered cholesterol drug
26 Sep 2025 13:39 GMT
Olivier Le MoalRegeneron Pharmaceuticals (NASDAQ:REGN) announced on Friday that the U.S. FDA approved a label expansion for its anti-cholesterol agent Evkeeza, marketed globally with Ultragenyx Pharmaceuticals (NASDAQ:RARE).
Accordingly, the injectable, …
About
© 1995-2025